Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Sanofi is writing Regeneron a $1 billion check — just to start. The French pharma giant is expanding its partnership with the US biotech to develop four next-generation, long-acting immunology antibodies, with up to $7 billion more in milestone payments on the table. The two companies, already behind the blockbuster eczema drug Dupixent, will split costs and profits equally under the new agreement.
Sanofi and Regeneron are taking their already-successful partnership to the next level. The French drugmaker announced it will pay Regeneron $1 billion upfront — plus up to $7 billion in additional milestone payments — to bring four new next-generation, long-acting immunology antibodies into their existing collaboration. The two companies also settled prior litigation tied to their partnership as part of the deal.
The expanded agreement builds on the duo's existing work together, most notably Dupixent (dupilumab), a blockbuster biologic approved for conditions like atopic dermatitis, asthma, and other inflammatory diseases. Under the new terms, costs and profits will be split equally between the two companies.
By the Numbers:
Why it matters: This deal signals major confidence in the future of immunology biologics, particularly long-acting antibody therapies. With Dupixent already generating billions in annual revenue, expanding the pipeline could reshape treatment options for patients with chronic inflammatory and immune-mediated conditions.
